Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 8/20 | 0.67 |
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD5 | P21918 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137393 | 1.00 | DRD2 (0.68) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL7137390 | 1.00 | DRD2 (0.68) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL24489427 | 0.87 | DRD2 (0.67) | DRD2SIGMAR1DRD3DRD4NFKB1 | |
| SCHEMBL17364235 | 0.87 | DRD2 (0.67) | DRD2SIGMAR1DRD3DRD4NFKB1 | |
| SCHEMBL17364173 | 0.87 | DRD2 (0.67) | DRD2SIGMAR1DRD3DRD4NFKB1 | |
| SCHEMBL21654482 | 0.85 | DRD2 (0.64) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL7130859 | 0.84 | DRD2 (0.69) | DRD2SIGMAR1DRD3 | |
| SCHEMBL7130854 | 0.84 | DRD2 (0.69) | DRD2SIGMAR1DRD3 | |
| SCHEMBL7130861 | 0.84 | DRD2 (0.69) | DRD2SIGMAR1DRD3 | |
| Pridopidine SCHEMBL166748 | 0.81 | DRD2 (1.00) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | DRD2 12/4885SIGMAR1 5/4885DRD3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.